Treatment and outcomes for early non-small-cell lung cancer: a retrospective analysis of a Portuguese hospital database

• Published in: Lung cancer management 2021-06, Vol.10 (2)
• Main Authors: Soares, Marta, Antunes, Luís, Redondo, Patrícia, Borges, Marina, Hermans, Ruben, Patel, Dony, Grimson, Fiona, Munro, Robin, Chaib, Carlos, Lacoin, Laure, Daumont, Melinda, Penrod, John R, O’Donnell, John C, Bento, Maria José, Gonçalves, Francisco Rocha
• Format: Article
• Language: English
• Subjects: non-small-cell lung cancer; non-squamous cell carcinoma; overall survival; real-world evidence; squamous cell carcinoma; stage I–IIIA; treatment patterns
• ISSN: 1758-1966; 1758-1974
• DOI: 10.2217/lmt-2020-0028

This observational study evaluated treatment patterns and survival for patients with stage I–IIIA non-small-cell lung cancer (NSCLC). Adults newly diagnosed with NSCLC in 2012–2016 at IPO-Porto hospital were included. Treatment data were available for patients diagnosed in 2015–2016. 495 patients were included (median age: 67 years). The most common treatments were surgery alone or with another therapy (stage I: 66%) and systemic anticancer therapy plus radiotherapy (stage II: 54%; stage IIIA: 59%). One-year OS (95% CI) for patients with stage I, II and IIIA NSCLC (diagnosed 2012–2016) were 92% (88–96), 71% (62–82) and 69% (63–75), respectively; one-year OS (95% CI) for treated patients with stage I–II or stage IIIA NSCLC (diagnosed 2015–2016) were 89% (81–97) and 86% (75–98) for non-squamous cell and 76% (60–95) and 49% (34–70) for squamous cell NSCLC. Treatment advances are strongly needed for stage I–IIIA NSCLC, especially for patients with squamous cell histology.